Milk Vesicle-Coated Chiral Peptide Nanoparticles Enable Oral Cancer Therapy and Boost Immunotherapy

The researchers synthesized a chiral peptide-gold supramolecular nanostructure through an aqueous growth method combining organothiol D-peptides with Au3+. This was then camouflaged with membranes from milk-derived extracellular vesicles. The nanoparticles were characterized for pharmaceutical properties and tested in vivo through oral administration in three mouse cancer models. Combination studies with anti-PD1 immunotherapy evaluated immune activation and T-cell responses.

Oral cancer therapy is a long-standing goal in oncology — it would dramatically improve patient quality of life and treatment compliance. This study overcomes two major barriers: peptide degradation in the gut (solved by using protease-resistant D-peptides) and poor absorption (solved by milk vesicle camouflage). The demonstration that an oral peptide nanomedicine can both directly kill cancer cells via p53 and enhance immunotherapy marks a significant advance in peptide-based cancer treatment.

This study sits at the intersection of several cutting-edge fields: chiral peptide chemistry, nanomedicine, milk exosome biology, and cancer immunotherapy. The concept of using D-peptides for protease resistance combined with biological membrane camouflage for oral delivery represents a sophisticated multi-engineering approach. If translatable, it could fundamentally change how peptide-based cancer therapies are administered.

All studies were conducted in mouse models — pharmacokinetics, toxicity, and efficacy may differ significantly in humans. The complex multi-component nanostructure (D-peptide + gold + milk vesicle membranes) presents significant manufacturing and regulatory challenges. Long-term safety of gold-containing nanoparticles administered orally is not established. The specific tumor accumulation mechanism and efficiency after oral delivery would need detailed characterization in larger animals before clinical translation.